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Whole genome sequence association analysis of
fasting glucose and fasting insulin levels in diverse
cohorts from the NHLBI TOPMed program
The genetic determinants of fasting glucose (FG) and fasting insulin (FI) have been studied
mostly through genome arrays, resulting in over 100 associated variants. We extended this
work with high-coverage whole genome sequencing analyses from ﬁfteen cohorts in NHLBI’s
Trans-Omics for Precision Medicine (TOPMed) program. Over 23,000 non-diabetic individuals from ﬁve race-ethnicities/populations (African, Asian, European, Hispanic and
Samoan) were included. Eight variants were signiﬁcantly associated with FG or FI across
previously identiﬁed regions MTNR1B, G6PC2, GCK, GCKR and FOXA2. We additionally
characterize suggestive associations with FG or FI near previously identiﬁed SLC30A8,
TCF7L2, and ADCY5 regions as well as APOB, PTPRT, and ROBO1. Functional annotation
resources including the Diabetes Epigenome Atlas were compiled for each signal (chromatin
states, annotation principal components, and others) to elucidate variant-to-function
hypotheses. We provide a catalog of nucleotide-resolution genomic variation spanning
intergenic and intronic regions creating a foundation for future sequencing-based investigations of glycemic traits.

A full list of authors and their afﬁliations appears at the end of the paper.
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T

ype 2 diabetes (T2D) and insulin resistance are complex
genetic conditions often characterized by disruptions of
normal levels of fasting glucose (FG) and fasting insulin
(FI)1. These traits are inﬂuenced by a spectrum of common to
rare genetic variation2–7 with most evidence coming from
genome-wide association studies (GWAS)8,9, exome arrays2,3,6,
whole-exome sequencing2, and small samples of low-pass wholegenome sequencing (WGS)4,10. These efforts have found over
100, mostly common (minor allele frequency (MAF) > 0.05),
variants associated with FG or FI, including those in non-coding
and intergenic spaces2–4,6,8,9. We expand on these previous studies by assessing common, low frequency (MAF < 0.05), and rare
(MAF < 0.01) variants through comprehensive WGS association
analysis in diverse population cohorts in NHLBI’s Trans-Omics
for Precision Medicine (TOPMed) program. The current study
aims to better understand the variants at GWAS loci through
multiple approaches including discovery and ﬁne-mapping in
both coding and non-coding regions as well as aggregate rare
variant testing using both protein-coding variants and intergenic
variants. In addition, we explore ancestry-speciﬁc results through
our four included race/ethnicities and one population group:
African, Asian, European, Hispanic, and Samoan, respectively.
Finally, we characterize all reported regions with annotations
including chromatin states, annotation principal components
(PCs), expression quantitative trait loci (eQTL), and others from
recent annotation accumulation efforts including the Diabetes
Genome Atlas (DGA).
Results
Phenotypes and genotypes in the NHLBI TOPMed program.
We identiﬁed and characterized common and rare variants associated with FG and (natural log-transformed) FI through association tests using WGS data from ﬁfteen cohorts in TOPMed
(Supplementary Table 1). As in prior quantitative trait analyses, we
excluded individuals with diabetes (by glycemia or medication),
resulting in a total sample size of 26,807 individuals with FG and
23,211 individuals with FI. This represents a diverse sample of four
self-reported race/ethnicities and one population group including
African, Asian, European, Hispanic, and Samoan, respectively, and
our total sample was >40% non-European (Supplementary
Tables 2–3). In addition to use of genetic ancestry adjustments in
our models (see the “Methods” section), we used participant’s selfreported race/ethnicity to assign individuals to one of ﬁve groups
for stratiﬁed analyses or inclusion as a covariate. Individuals were
given a single label to infer their ancestry, but each group represents a diverse cross-section of race, culture, or admixture. Trait
measures were harmonized across cohorts and assays and adjusted
for self-reported race/ethnicity, study age, sex, and body mass
index (BMI; Supplementary Tables 2–3, “Methods”). We assessed
60 M variants from the TOPMed Freeze 5b WGS data freeze for
each trait using single-variant testing (minor allele count, MAC >
20) in pooled and race/ethnicity-speciﬁc approaches. We used a
signiﬁcance threshold of P < 1.0 × 10−9 as has been established for
WGS studies including African ancestry11. We also separately
report signals identiﬁed with P < 5.0 × 10−8 as suggestively associated with either trait. These suggestively associated signals are
reported to characterize potential regions of interest with our
available annotations for use in future higher-powered studies. We
further performed rare variant testing (MAF < 0.01) using aggregate burden and SKAT tests in both gene centric and genetic
region approaches. We computed 95% credible sets for each distinct common variant signal conditioned on any other identiﬁed
signal at the locus (“Methods”, Supplementary Data 1). 99%
credible sets are also reported for signals identiﬁed through the
pooled analysis (Supplementary Data 2), with a median size of 12
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variants. This is 20% smaller than a recent multi-ethnic GWAS of
glycemic traits12 which reported a median 99% credible set
size of 15.
Whole-genome sequence signiﬁcant associations with fasting
glucose and insulin. We identiﬁed eight distinct variants signiﬁcantly associated with FG or FI across ﬁve gene regions in the
pooled race/ethnicity analysis (P < 1.0 × 10−9, Table 1). These
include previously identiﬁed MTNR1B, G6PC2, GCK, GCKR, and
FOXA2 gene regions (Supplementary Data 3–4). MTNR1B had a
distinct secondary signal after conditioning on the lead variant.
G6PC2 had three distinct association signals, one of which was
rare (MAF < 0.01), as determined by sequential conditional analysis. These distinct secondary and tertiary signals are also
reported in Table 1 (locus-wide signiﬁcance threshold of
1.0 × 10−5, “Methods”) and further described in the following
sections. Manhattan and QQ plots for single variant analyses of
FG and FI are shown in Supplementary Fig. 1.
Our signiﬁcantly associated variants replicate previous GWAS
ﬁndings, which are summarized in Supplementary Data 3–4. We
further characterize these variants in the context of sequencing
and related available resources as summarized in Fig. 1. We used
the Diabetes Epigenome Atlas (DGA) and TOPMed resources to
provide functional annotations including chromatin states,
annotation principal components (aPCs)11 that each provide a
summary of related functional annotations via PCA (“Methods”),
and expression quantitative trait loci (eQTL) from adipose,
pancreas, liver and skeletal muscle. In addition to variant
descriptions in Fig. 1, regional locus plots with tissue-speciﬁc
annotations for reported loci in Supplementary Fig. 2, and
associations of reported loci with related traits in Supplementary
Fig. 3 and Supplementary Data 5. Selected regions are further
described based on the data below.
MTNR1B intronic variant rs10830963 (P = 9.1 × 10−46) has
been characterized as a strong signal for insulin secretion13; this
variant is in a weak transcription chromatin state in islets, is a
metabolite QTL for glucose14,15, and is a pancreatic-islet-speciﬁc
eQTL associated with the expression of MTNR1B16. Identiﬁed
after conditioning on the primary variant rs10830963 in the
MTNR1B region, intronic variant rs73560545 occurs upstream of
the primary signal and had a lowering effect on FG, in contrast to
the primary signal which had a glucose-raising effect. While this
is a well-known region in the context of these traits, this
secondary variant at rs73560545 has not been previously
identiﬁed in the reviewed literature (Supplementary Data 3–4).
The GCKR locus had a signiﬁcant association with both FG
and FI at rs1260326 (P = 6.1 × 10−21, 7.2 × 10−13, respectively)
with functional activity suggested by its relatively high aPCEpigenetics and aPC-Transcription-Factor values. This variant is
also an eQTL and pQTL associated with many genes and
proteins, most relevantly with insulin17. GCKR and rs1260326
have been previously described in previous studies for both traits
(Supplementary Data 3–4).
The FOXA2 locus has also been previously found to be
associated with glycemic traits, regulating gene expression for
glucose sensing in pancreatic beta cells18. We observe one FGassociated signal at rs3833331 (P = 5.4 × 10–10), a variant
moderately linked to previously identiﬁed FOXA2 lead variants
rs6048205 and rs6048216, and based on conditional analysis is
likely the same signal. The variant rs3833331 is in the 3′ UTR of
the gene and classiﬁed as a CAGE promoter, GeneHancer, and
SuperEnhancer. It is in an active TSS chromatin state for both
pancreas and islets. Our identiﬁed variant rs3833331 is frequent
in African individuals, while it has relatively low frequency in
both European and Hispanic race/ethnicities.
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aChromosome, position(Hg38), reference allele, alternative allele of the genetic variant with the lowest P-value and highest posterior probability representing a distinct association at a locus.
bIndicates secondary signal.
cIndicates tertiary signal for association at signiﬁcance level P < 1 × 10−5 and MAC > 20 after conditional analysis.
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Rare variant aggregate testing performed using both genecentric and genetic region approaches identiﬁed one signiﬁcantly
associated region with FG at the known G6PC2 locus, described
in the next section (Supplementary Data 6–7). No rare variant
aggregate signals were found to be associated with FI that were
not composed mostly of singletons (Supplementary Data 8–9).
Manhattan plots for region-based rare variant aggregate analysis
in Supplementary Fig. 4.
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Table 1 Distinct signals at loci signiﬁcantly associated with glycemic traits FG and FI in TOPMed, P < 1 × 10−9.
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Reﬁnement of the multi-allelic associations at the known
G6PC2 locus. At the known FG and T2D-associated G6PC2
locus2,3, we observed several previously identiﬁed variant associations
with FG (Fig. 2). In single variant analyses, we identiﬁed three distinct
association signals, the third of which was a previously identiﬁed
association after conditioning on two previously reported common
GWAS variants, rs560887 (primary signal, P = 6.8 × 10−37) and
rs540524 (secondary signal, P = 9.9 × 10−14). The rare missense
variant rs2232326 (tertiary signal, P = 5.0 × 10−6) is annotated19 by
the aPCs as disruptive and likely damaging, with a score falling in the
top 7% distribution of the aPC representing “protein function” (aPCProtein Function = 31.5, top 7% genome-wide). In addition,
rs2232326 appears to be highly conserved, with a score falling in the
top 0.13% of the distribution of an aPC representing “conservation”
(aPC-Conservation = 28.8, top 0.13% genome-wide). The genomic
region surrounding rs2232326 is annotated to be in a weakly transcribed chromatin state, relative to the genome, in islets and this
variant is near the transcription end site (Fig. 2). The frequency of the
C allele at rs2232326 was <0.01 in all race/ethnicity groups except for
the Asian group where the frequency was 0.03 (gnomAD: East Asian
AF = 0.05, Overall AF = 0.01). In aggregate gene-centric testing of all
75 rare missense variants in G6PC2, this previously identiﬁed rare
(MAF = 0.01) variant rs2232326, along with variant rs2232323
(MAF = 0.01), contributed the most to the signiﬁcant association test
statistic (PBurden,1,1 = 1.4 × 10−10, Supplementary Data 6).
Given the multiple distinct signals at G6PC2, we performed a
haplotype analysis to evaluate the contribution of rare variants and
identify allele-speciﬁc effects. We extended the haplotype analysis of
Mahajan et al.3 (rs560887, rs138726309, rs2232323, rs492594) to
include our secondary (rs540524) and tertiary (rs2232326) signals.
Our secondary signal is in moderate linkage (r2 = 0.58) to the
previously haplotyped rs492594 and the effect allele A has a
glucose-raising effect in both marginal and conditional analyses
(Supplementary Table 4 and Table 1). We observed consistent
direction of effects as the previous haplotype analysis, demonstrating the reliability of associations identiﬁed in the present TOPMed
sample. Both haplotypes containing the C allele of the tertiary signal
at rs2232326, the variant with the largest effect size included in the
analysis, had glucose-lowering effects. The largest glucose-lowering
effects at G6PC2 were observed at the two haplotypes each carrying
a rare allele: rs2232326 (rs560887-C, rs138726309-C, rs2232323-A,
rs492594-C, rs540524-G, rs2232326-C, Beta = −0.15 +/− 0.00002)
and rs2232323 (rs560887-T, rs138726309-C, rs2232323-C,
rs492594-G, rs540524-A, rs2232326-T, Beta = −0.11+/−0.00008,
Supplementary Table 4).
Additional suggestive associations with fasting glucose and
insulin. We further report twelve distinct variants suggestively
associated with FG or FI across ten gene regions in the pooled
race/ethnicity
analysis
and
ancestry-speciﬁc
analyses
(P < 5.0 × 10−8; Table 2). These include previously identiﬁed
SLC30A8, TCF7L2, and ADCY5 gene regions (Supplementary
Data 3–4). Other regions not previously identiﬁed include APOB,
PTPRT, ROBO1 and those described in the ancestry-speciﬁc
section below. SLC30A8 and PTPRT have distinct secondary
signals identiﬁed through conditional analysis, which are also
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Fig. 1 Characterization of signiﬁcant and suggestive single-variant signals associated with fasting glucose and fasting insulin in TOPMed. TOPMed
features of distinct, signiﬁcant and suggestive signals associated with fasting glucose and fasting insulin (log-transformed) in pooled analysis. P-values
(unconditional −log10-transformed) for glycemic and related traits (HbAa1c and type 2 diabetes) and effect allele frequency (with respect to the pooled
analysis effect allele) across race/ethnicities in TOPMed are reported. Chromatin states at relevant tissues were drawn from two sets of experiments from
DGA46,47; annotation PCs provide summaries of multi-faceted variant function; variants that are signiﬁcant eQTLs in relevant tissues are denoted. EAF,
effect allele frequency for TOPMed sample; EnhA1, Active Enhancer 1; EnhA2, Active Enhancer 2; Het, Heterochromatin; Quies, Quiescent/Low; ReprPC,
Repressed PolyComb; ReprPCWk, Weak Repressed PolyComb; TssA, Active TSS; TssFlnk, Flanking TSS; TxWk, Weak Transcription; ZNF/Rpts, ZNF genes
& repeats.

reported in Table 2 (locus-wide signiﬁcance threshold
P < 1.0 × 10−5). We outline these suggestive signals and the corresponding gene regions below to provide annotation and
description and to provide context for investigation of these
signals in future, larger studies.
In the ADCY5 region, variant rs72964564 (P = 2.8 × 10−8)
showed suggestive association with FG and is highly linked
(r2 = 0.86 in the present study sample) with the known FGassociated variant rs11708067. Both ADCY5 variants are
designated GeneHancer and SuperEnhancer variants, and
rs72964564 is in an active enhancer state for adipose tissue and
is an eQTL associated with ADCY5 expression in pancreatic
islets16. ADCY5 and rs72964564 have been previously identiﬁed
in studies of FG (Supplementary Data 3–4).
Near the APOB region a suggestively associated variant at
rs478588 (P = 2.9 × 10−9) has not previously identiﬁed (Supplementary Data 4). Variant rs478588 has robust associations with
lipid traits20 and signiﬁcant parent-of-origin effects on metabolic
traits21. Lipid traits have been studied for pleiotropy with
glycemic traits but have been inconclusive with respect to APOB.
Replication was attempted in UK-BioBank (UKBB) with
consistent direction of effect and P = 0.01, but it should be noted
UKBB sample used was not based on WGS data (Supplementary
Table 5).
We identiﬁed a pair of suggestively FG-associated signals in
islet-speciﬁc active enhancer regions at the known SLC30A8
locus. The primary signal is at variant rs35859536
(P = 1.0 × 10−9), which is an intergenic variant 2.5KB downstream of SLC30A8. This variant is highly linked (r2 > 0.95) to
previously identiﬁed lead variants rs11558471 and rs3802177 at
SLC30A8, both of which are in the 3′ UTR. This is a known T2D
susceptibility locus and has been identiﬁed as associated with
triglyceride levels22. Our lead variant is also signiﬁcantly
associated with T2D in TOPMed (Supplementary Data 5)23. To
evaluate potential causal variants (“Methods”) we performed
credible set analyses and found rs35859536 has a posterior
4

probability (PP) of 0.48; other variants in the 95% credible set
with PP of at least 0.05 were either missense or in the 3′ UTR, are
highly linked with this lead variant (r2 > 0.97), and were
signiﬁcantly associated with FG in previous studies2,8,24. Our
lead variant, along with other previous lead variants, is in an
active enhancer 2 region for islets; rs35859536 is also mapped as
an accessible chromatin site in islet of Langerhans given
inﬂammatory-inducing cytokine exposure25. Replication of these
signals was attempted in the METSIM cohorts, and we observe
nominal signiﬁcance of the primary signal with a consistent
direction of effect, while the secondary signal was too low
frequency in this cohort to estimate an effect (Supplementary
Table 6).
The secondary suggestively FG-associated signal at the
SLC30A8 locus is at variant rs542965166 (P = 1.9 × 10−6). This
intergenic variant is only observed in individuals in the Asian
population (Asian EAF = 0.007); this race/ethnicity-speciﬁcity is
replicated in gnomAD26 where the allele is only observed in East
Asians at a rare frequency. This secondary, race/ethnicity-speciﬁc
signal is not highly linked to other variants in the region, which
may indicate that this is a distinct, secondary signal and requires
further follow-up in an Asian population.
Upstream of the ROBO1 locus we identiﬁed a suggestively
novel (to the best of our knowledge) FI-associated rare variant,
rs539973028 (P = 4.7 × 10−8). This locus has previously been
studied for SLIT-ROBO signaling and expression in T2D
complication diabetic retinopathy27. ROBO1 has been associated
with the glycemia-related traits of BMI and waist-to-hip
ratio28–30 and is commonly expressed in muscle and skin31. This
variant is only observed in the African population of TOPMed
and gnomAD26. It is intergenic and in a weakly transcribed
region in islets.
We identiﬁed a pair of distinct, suggestively novel (to the best
of our knowledge) rare variant signals associated with FI near the
PTPRT gene (Table 2). The primary signal, rs185250851
(P = 2.1 × 10−8), is an intronic variant. It is rare in all tested
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population groups and not observed in Asian individuals, as
validated in gnomAD26. The secondary signal at variant
rs78618809 (P = 5.9 × 10−6) is in an intergenic region. This
variant is within the top 5% of variants with respect to an aPC
representing “Distance to TSS/TSE,” a composite measure of
individual annotations indicating low variant distance to the
endpoints of the intergenic region. This variant is rare overall, but
observed frequently (EAF = 0.07) in the African ancestry
population. This gene has previously been associated with BMI,
which has moderate genetic correlation (previously estimated as
ρg = 0.48) with FI20,21. The expression of this gene is most
commonly associated with variants as eQTLs in pancreas in
GTEx31. The multi-ethnic TOPMed sample permits the identiﬁcation of this signal, which requires a sufﬁciently diverse sample.

0
20

Secondary

15

1.0
0.8
0.6
0.4
0.2
0.0
NA

2:168900420:A:G
rs540524

10
5
0
20

1.0
0.8
0.6
0.4
0.2
0.0
NA

Tertiary

15

10

2:168907981:T:C
rs2232326

5

APC 9 APC 3 APC 2 APC 1

Skeletal
Liver
Muscle

Islets Adipose

0

20
15
10
5
50
40
30
20
10
40
30
20
10
25
20
15
10
5

Fig. 2 Regional investigation of three conditionally signiﬁcant signals
associated with fasting glucose in the G6PC2 locus in TOPMed.
Regional association plot of −log10 P values by genomic position for
sequential conditional single-variant analyses. The linkage disequilibrium
(r2) between the primary signal (rs560887, 2:168906638:T:C), as
deﬁned by the highest posterior probability, and variants in the region for
each panel as calculated in TOPMed is indicated in the colors of the
points. The chromatin states at four relevant tissues47 and annotation
PCs are provided across the region. APC1, APC Epigenetics, APC2, APC
Conservation, APC3, APC Protein, APC9, APC Distance to TSS/TSE;
EnhA1, Active Enhancer 1; EnhA2, Active Enhancer 2; Het,
Heterochromatin; Quies, Quiescent/Low; ReprPC, Repressed PolyComb;
ReprPCWk, Weak Repressed PolyComb; TssA, Active TSS; TssFlnk,
Flanking TSS; TxWk, Weak Transcription; ZNF/Rpts, ZNF genes &
repeat.

Race/ethnicity-speciﬁc analyses associated with fasting glucose
and insulin. In race/ethnicity-speciﬁc analyses, we observed two
not previously identiﬁed race/ethnicity-speciﬁc rare variant suggestive associations with FG in individuals of the Hispanic/Latinx
population (Table 2). The ﬁrst signal, rs1328056 (P = 3.6 × 10−8),
is an intronic variant in the HS6ST2 gene, which has been associated with obesity and impaired glucose metabolism in mouse
studies13. The second signal is an intergenic variant near the
ATPSCKMT gene, rs13361160 (P = 3.1 × 10−8) which is associated with eosinophil counts, a measure that has been negatively
correlated with FG14. We would require further data from individuals from the Hispanic/Latinx population in order to replicate
these suggestive signals.
We identiﬁed two suggestively novel (to the best of our
knowledge) race/ethnicity-speciﬁc rare alleles associated with FI.
In the European population, rs775018107 (P = 4.5 × 10−8) at the
LINC00704/LINC00705 locus was suggestively associated with FI
(Table 2). We also identiﬁed a suggestive FI association in the
Samoan population cohort at rs117592405 (P = 3.3 × 10−8); this
intronic variant was not replicated in an independent Samoan
cohort using imputed genotypes (N = 1401, Supplementary
Table 7).
Enrichment of trait-associated variants in chromatin states. We
assessed whether our trait-associated variants were found more
often than expected in a particular chromatin state using the tool
GREGOR (Genomic Regulatory Elements and Gwas Overlap
algorithm)15 (“Methods”). We observe that fasting glucoseassociated variants are found more often in “Active Enhancers”,
“Weak Transcription”, and “Genic Enhancer” chromatin states in
Islets (P < 0.05, Supplementary Table 8). This complements
ﬁndings from Chen et al.12 showing similar enrichment of glycemic trait-associated signals in islet enhancers.
Discussion
In this paper, we leveraged high-coverage WGS data in large
multi-ethnic population-based cohorts to assemble a comprehensive catalog of nucleotide-resolution genomic variation associated with the key diabetes-related quantitative traits FG and FI.
Our analysis covered intergenic and intronic regions to a MAC of
20 in single variant analysis and combines base pair variation
with tissue-speciﬁc epigenomic annotation to illuminate variantto-function hypotheses in diabetes pathobiology.
A strength of the present analysis is the inclusion of individuals
from 15 cohorts, comprised of four major race/ethnicity groups
and one population group(African, Asian, European, Hispanic/
Latinx, and Samoan, respectively). Some of our reported regions
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Intergenic
44KB upstream
ncRNA intronic
ncRNA intronic

Annotation
rsID

rs35859536
rs542965166
rs478588
rs7903146
rs72964564
rs1328056
rs13361160
rs185250851
rs78618809
rs539973028
rs775018107
rs117592405
C
T
A
T
A
G
C
A
T
C
G
G

EA

8:117179236:C:T
8:117258547:C:Tb
2:21074277:A:G
10:112998590:C:T
3:123335923:A:C
13:96407609:A:G
5:10169711:T:C
20:42752773:G:A
20:43230137:C:Tb
3:79812347:C:A
10:4656482:GAAAAT:G
3:118656074:T:Gc
SLC30A8
Pooled
Fasting glucose

MarkerIDa
Nearest gene
Population
Trait

Table 2 Distinct signals at loci suggestively associated with glycemic traits FG and FI in TOPMed, P < 5 × 10−8.
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P-value

SE

Conditioned on
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were either mostly or exclusively present in a single race/ethnic
group. These include the secondary SLC30A8 variant
rs542965166 only observed in the Asian group, ROBO1’s
rs539973028 only present in African group, and others. Previous
genetic studies of glycemic traits have included samples primarily
from individuals of European ancestry, but increasingly a larger
degree of African ancestry. The most recent meta-analysis by the
MAGIC consortium included ~30% non-European ancestry
individuals, demonstrating that a number of trait-associated loci
that would have been undetected in samples exclusively of European ancestry18. While extending the genetic ancestries studied
beyond European populations, the MAGIC results were subject to
the limitation of imputation by the 1000 Genomes Project
reference panel, so most rare and ancestry-speciﬁc variation was
still not assessed. In addition, we observe a 20% decrease in
average 99% credible set size from the MAGIC results suggesting
value of WGS in ﬁne-mapping.
This analysis beneﬁts from the availability of whole-genome
sequencing data provided by the TOPMed Program of the
NHLBI’s Precision Medicine Initiative10,32. Previous studies have
been limited by reliance on imputation or minimal sample sizes
for data with sequencing paired with glycemic phenotypes. The
GoT2D study has performed WGS in a limited sample, contributing to the larger DIAMANTE meta-analysis of summary
statistics but relying on imputation for complete genotyping of
most samples33. The UKBB study includes a large set of primarily
European individuals with whole-exome sequencing; however,
the sample size with measured fasting glycemic traits is limited as
described in the validation study. One of the most expansive
efforts, a MAGIC collaboration8,34, has performed extensive
analyses for glycemic traits, but results rely primary on Exome
Chip data and thus have limited coverage of intergenic and
intronic regions6. Our signiﬁcant ﬁndings replicate previous
GWAS ﬁndings in terms of gene regions, but we are able to
characterize these regions in great detail and report on speciﬁc
variants which may not previously described in these known
regions, such as the secondary MTNR1B-associated variant.
In addition to reporting signiﬁcant and suggestive associations,
we provide detailed characterization of each locus in terms of
functional annotations, chromatin states, quantitative trait loci,
related trait associations and more. The G6PC2 in particular was
described in terms of allelic effects and provided functional
characterization of low-frequency signal, demonstrating the
glucose-lowering effects of rare alleles and islet-speciﬁcity of this
locus’s associations. Many of our reported regions lie in enhancer
or transcription start site chromatin states, and we particularly see
signiﬁcant enrichment in enhancer states in islets. This agrees
with ﬁndings of previous GWAS and the expected relevant tissues
for glycemic traits. We provide this data and the visualizations for
use in future investigation of these loci.
A limitation of this study is our smaller sample size compared
to the most recent GWAS. Our signiﬁcant single variant results
are all found near previously identiﬁed gene regions. Also, many
of our suggestively novel results lack substantiating replication,
particularly those which are race/ethnicity speciﬁc. We analyzed
independent studies with genetic data to investigate associations
signiﬁcant in TOPMed; we were unable to replicate potentially
novel signals in these external cohorts. This may be attributable to
limitations in the available replication studies’ samples with
respect to size, race/ethnicity and imputed versus WGS genotypes. To support the understanding of these signals, we consider
a set of tissue-speciﬁc chromatin states, an effort that would
beneﬁt from further tissue-speciﬁc characterization across functional measures. This could also help inform the underlying
biological mechanisms of glycemic regulation and its role in
diabetes.
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This multi-ethnic WGS study provides the foundation for
future sequencing-based investigation of glycemic traits. Our
results from common and rare variant analysis comprised multiple suggestive hits, including those with exceedingly rare variants that require further investigation, indicating the potential
for the identiﬁcation of novel signals given larger sequencing
studies and external validation studies. The value of diverse studies like TOPMed is further evidenced by the speciﬁcity of such
signals to certain populations and cohorts. This value is also
demonstrated by the intronic and intergenic location of many
such suggested signals. These signals, in both single variant and
rare variant set-based testing, indicated that many associations lie
outside gene boundaries and it is important to perform genomewide single variant testing but also complement gene-centric RV
testing with region-based RV testing to fully capture signal.
Future TOPMed study phases will permit the continued investigation of these signals empowered by increased sample sizes, with
future directions including detailed ﬁne-mapping of signal
regions and assessment of glycemic trait heritability. To support
future research, all results from this analysis have been made
available to the research community through the Type 2 Diabetes
Knowledge Portal (Genetic Association Data will be released in
January 2021)17.
Methods
Whole-genome sequencing. Whole-genome sequencing of blood samples for all
participants included deep coverage (>30x on average) sequencing from blood
samples provided by the NHLBI TOPMed program. Sequencing was performed
across six centers (Broad Institute of MIT and Harvard, Northwest Genomics
Center, New York Genome Center, Illumina Genomic Services, Macrogen, and
Baylor College of Medicine Human Genome Sequencing Center) as previously
described35. The TOPMed Informatics Research Center at the University of
Michigan performed data harmonization and joint variant discovery and genotype
calling, requiring DNA sample contamination below 3% and at least 95% of the
genome with at least 10x coverage. Freeze 5b was aligned to GRCh38 reads from
the 1000 Genomes Project reference sequences36. The samples were further processed by a centralized pipeline by the TOPMed Data Coordinating Center at the
University of Washington, where further quality control and sample-identity
resolution were performed, including sex and relatedness concordance and selection of variants with missingness <5% and QUAL > 127. Variants were also
checked via an excess heterozygosity ﬁlter (EXHET), which removed the variant if
the Hardy-Weinberg disequilibrium p-value was <1 × 10−6, after accounting for
population structure. After processing, Freeze 5b contained 54,508 samples with
438 million single nucleotide variants (SNVs) and 33 million short insertiondeletion variants.
Population structure principal components were calculated across all Freeze 5b
TOPMed participants using PC-AiR; a genetic relatedness matrix was calculated
across all Freeze 5b TOPMed participants using PC-Relate accounting for
population structure. Race/ethnicity was determined by self-report from each
study. Self-reported race/ethnicity was used in conjunction with principal
component and/or genetic relatedness matrix adjustment to control for both
genetic and individually identiﬁed ancestry37.

Phenotype harmonization. Phenotype harmonization proceeded following a
protocol deﬁned by the TOPMed Diabetes Working Group for participating
TOPMed studies. Duplicated individuals were excluded following the TOPMed
Diabetes Working Group protocol. Within a study, monozygotic twins were
retained and the duplicate to be kept was chosen based on veriﬁcation of cohort
characteristics, including proper cohort sequencing center designation, and then by
highest call rate. Across studies, duplicates were selected by removing missing trait
data, prioritizing population-based cohorts, and retaining individual records with
the longest follow-up period. All study participants provided informed consent and
each study was approved by their respective institutional review boards.
Glycemic traits (fasting glucose (FG) and fasting insulin (FI)) were analyzed for
individuals who did not have diabetes at the time of glycemic trait measurement.
This subset was deﬁned as those not taking anti-diabetes medication, with fasting
glucose <7 mmol/l and/or HbA1c < 6.5%. For individuals with multiple blood
draws, the earliest exam or most complete exam was used. Age, sex, and BMI
covariates were reported at the time of glycemic trait measurement. Fasting was
deﬁned to be at least 8 h without food or drink; measurements from blood were
converted to plasma values using a 1.13 correction factor38. The units for glucose
are mmol/l; units for insulin are pmol/l. Fasting insulin was natural logtransformed prior to analysis in order to address non-normality.
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Study sample and power. The present analysis included 23,211 (FI) and 26,807
(FG) individuals from the NHLBI TOPMed program. The cohorts included consist
of participants of self-reported African American (FI n = 6803; FG n = 7174), East
Asian (FI n = 572; FG n = 2217), European (FI n = 13,281; FG n = 14,513), Hispanic/Latinx (FI n = 1641; FG n = 1989), and Samoan (FI n = 914; FG n = 914)
race/ethnicity. Our analysis of fasting insulin included 14 cohorts and fasting
glucose included 15 cohorts. The sample is predominantly of European race/ethnicity (FI 57.2%; FG 54.1%) and female (FI 66.5%; FG 65.2%); full cohort
descriptions are given in Supplementary Tables 2 and 3.
We performed a post hoc power calculation to evaluate the power to detect
genetic signal at the genome-wide threshold for statistical signiﬁcance of 5 × 10−8.
Given the study sample size, this analysis was powered to detect 0.54–4.21% and
0.57–4.21% percent variation in glycemic trait explained by a genotype in race/
ethnicity-speciﬁc analyses for FG and FI, respectively. The pooled study including
all samples was powered to detect 0.16% and 0.17% percent variation in glycemic
trait explained by a genotype for FG and FI, respectively.

Single-variant analysis. We performed single variant analysis in Freeze 5b of
TOPMed using race/ethnicity-speciﬁc and pooled approaches. We tested
64,675,008 variants for associations with FG and 58,759,883 with FI in both pooled
and race/ethnicity-speciﬁc analyses, and restricted analysis to variants with minor
allele count >= 20. We used linear mixed effects models and adjusted for age, age
squared, sex, body mass index, study-race/ethnicity, with heterogeneous variance
permitted across study-race/ethnicity groups and empirical kinship for relatedness
and population structure. Models were ﬁt using GENetic Estimation and Inference
in Structured samples (GENESIS)39 in the Analysis Commons cloud-computing
platform40. P-Values reported are for a two-sided Wald test from the mixed model.
Fasting glucose and natural log-transformed fasting insulin were used as outcomes
in separate models. We deﬁne the standard genome-wide threshold for statistical
signiﬁcance as 1 × 10−9. We also report variants with P < 5 × 10−8 as suggestively
associated to provide context for regions of interest for future, higher-powered
studies.
Stepwise conditional analysis was performed at each identiﬁed locus, deﬁned to
be a 500 kb region centered on the most signiﬁcant variant, in order to identify
distinct signals. This analysis proceeded by ﬁrst including the most signiﬁcant
variant as a covariate, and repeating until no variants were associated with the
phenotype with p-value <1 × 10−5. For each distinct signal, a ﬁnal model was run
conditioning on the set of other distinct signals; we report these potentially distinct
signals.
Towards ﬁne-mapping the identiﬁed loci, we generated 95% credible sets to
investigate likely causal variants (LocalZoom). For each locus, we calculated Bayes
factors for all variants from their single variant p-value; p-values were taken from
conditional analyses on all other identiﬁed variants at the locus where multiple
distinct signals were identiﬁed in the stepwise conditional analysis. We calculated
posterior probability of association (PP) of each variant as the proportion
contributed to the summation of all BFs in the region. The variants were sorted by
descending PP, indicating decreasing probability that the variant is truly associated
with the glycemic trait. The 95% credible set was constructed by including variants,
starting with the highest PPA, until their cumulative PPA exceeded 0.95. 99%
credible sets were similarly constructed for association signals from the pooled
analysis only.

Rare variant analysis. We performed gene-based and genetic region aggregate
testing to identify sets of rare variants associated with fasting glucose and logtransformed fasting insulin. We ﬁrst ﬁt a heteroscedastic linear mixed model for
fasting glucose and log-transformed fasting insulin. Both traits were adjusted for
age, age2, sex, body mass index (BMI), study-race/ethnicity group indicators, and
ten population structure principal components. A variance component was
included for the empirically derived sparse kinship matrix and residual variances
were permitted to be different for study-race/ethnicity groups to account for family
relatedness, population structure, and study-race/ethnicity differences.
The heteroscedastic linear mixed model was used to perform variant set
analyses for rare variants with MAF < 1%. Sets were deﬁned by genetic regions and
gene-centric categories. Genetic regions allowed the complete analysis of the
genome, particularly non-coding regions that have not been previously captured by
arrays. The regional analysis used 2 kb sliding windows to scan the genome with
1 kb skip length. The gene-centric analysis examined all protein-coding genes in
Ensembl using functionally determined masks to aggregate variants together by
coding and non-coding annotations. Coding annotations were used to deﬁne three
SNV ﬁlters categorized by GENCODE based on consequence: (a) putative loss of
function (stop gain, stop loss, splicing), (b) missense, and (c) synonymous variants.
Leveraging the whole-genome sequencing, we used non-coding annotations to test
sets of variants that are not protein coding. We constructed masks (d)
characterized as promoters given they were within +/− 3 kb of a transcription start
site with CAGE signal overlay, or (e) characterized as enhancers given they were
identiﬁed by GeneHancer with CAGE signal overlay.
The burden test and SKAT were used for testing the association of the rare
variant sets and FG and FI. In these approaches, a weight based on the MAF can be
used to upweight rarer variants. We considered two common weighting schemes
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based on wj ¼ BetaðMAFj ; a1 ; a2 Þ, where a1 ¼ 1 and a2 ¼ 25 or a1 ¼ 1 and
a2 ¼ 1.
Statistical signiﬁcance was deﬁned for each glycemic trait, separately for genecentric and genetic region analysis. For gene-centric analysis, a threshold was deﬁned
by a Bonferroni-corrected signiﬁcance threshold of α  0:05=ð120; 000Þ ¼ 4 ´ 107 ,
correcting for all ﬁve masks and all protein-coding genes when considering the
minimum p-value across the burden and SKAT tests (Supplementary Table 9). The
threshold for the genetic region analysis was determined given the total number of
2 kb sliding windows tested, yielding a Bonferroni-corrected threshold of
α  0:05=ð2:68 ´ 106 Þ ¼ 1:86 ´ 108 . We report sets that include variant(s) with
effective minor allele count greater than ﬁve and that are not exclusively composed
of singletons; complete results based on the signiﬁcance threshold are provided in
Supplementary Data 6–9.
Haplotype analysis. We performed haplotype analysis for variants associated with
fasting glucose. This analysis considered a set of 18,071 unrelated individuals,
identiﬁed by PC-AiR41 by the TOPMed Program with a threshold of third-degree
relatives. We performed regression of fasting glucose on haplotype using a two-step
EM algorithm on the unphased genotypes, as implemented in the haplo.stats R
package42. The posterior probabilities of haplotypes were computed for variants in
the G6PC2 gene; the variants were included based on the variants included in a
previous G6PC2 haplotype analysis, variants driving the G6PC2 missense set signal,
and distinct G6PC2 signals from the single variant analysis. The association was
adjusted for age, age2, sex, body mass index, study-race/ethnicity, and ten population structure principal components.
Annotation. In order to characterize the functional impact of associated variants,
we assembled functional annotations from multiple publicly available databases.
We considered annotations from the Diabetes Epigenome Atlas, FAVOR, InsPIRE,
and GTEx projects. From the Diabetes Epigenome Atlas, we obtained chromatin
states from four tissues relevant to glycemic traits: adipose, islet, liver, and muscle.
These were available from two experiments, Parker lab ChromHMM 13-state
model under accession TSTSR679993 & AMP-T2D ChromHMM 18-state model
under accession TSTSR043890. We also report annotation PCs from the FAVOR
database43, which are summaries calculated as the ﬁrst principal component of
individual functional annotations across functional categories including conservation, epigenetics, local nucleotide diversity, mutation density, protein function, proximity to TSS/TSE, proximity to coding, and transcription factor binding.
The individual annotations contributing to the aPCs are previously described19.
Annotation PCs are calculated at the variant level and reported as PHRED-scaled
scores derived from the ﬁrst PC from the category’s PCA, providing the interpretation that variants with scores >10 are in the top 10% of category across all
TOPMed variants. We obtained pancreatic islet-speciﬁc signals from the InsPIRE
consortium and tissue-speciﬁc signals from the GTEx project (Version 8) to assess
colocalization with gene expression at signal variants and those highly linked to
signal variants via look-up. We reported eQTLs in the following tissues, reported
for their importance in glycemic phenotypes: adipose subcutaneous, adipose
visceral, muscle skeletal, and pancreas.

expected number of variants to lie within each chromatin state. This was compared
to the observed number of variants in each chromatin state to generate a P-value.
Any P-values <0.05 are reported in the text and Supplementary Table 8.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The summary results generated during this study are available at the AMP-T2D Portal,
http://t2d.hugeamp.org/. Fasting Insulin: https://t2d.hugeamp.org/dinspector.html?
dataset=TOPMed_frz5b_pooled_FI_WGS. Fasting Glucose: https://t2d.hugeamp.org/
dinspector.html?dataset=TOPMed_frz5b_pooled_FG_WGS. Accession codes for
genotype and phenotype ﬁles by cohort may be found in Supplementary Table 1.

Code availability
This study did not rely on custom code or mathematical algorithms.
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